{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:45:00Z","timestamp":1790775900232,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd005385.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T00:00:00Z","timestamp":1334707200000}}],"reference-count":103,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005385.pub3","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T15:36:01Z","timestamp":1334244961000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recombinant human activated protein C for severe sepsis in neonates"],"prefix":"10.1002","author":[{"given":"Ranjit I","family":"Kylat","sequence":"first","affiliation":[{"name":"The University of Arizona; Section of Neonatology and Developmental Biology, Department of Pediatrics; 1501 N Campbell Ave PO Box 245073 Tucson Arizona USA 85724-5073"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"University of Toronto; Departments of Paediatrics, Obstetrics and Gynaecology and Institute of Health Policy, Management and Evaluation; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,4,18]]},"reference":[{"key":"10.1002\/14651858.CD005385.pub3-BIB0001|cit1","first-page":"1289","article-title":"Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure","volume":"26","author":"Albuali","year":"2005","journal-title":"Saudi Medical Journal"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1542\/peds.113.1.7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis","volume":"113","author":"Barton","year":"2004","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0003|cit3","unstructured":"Eli Lilly Xigris\u00ae- results in pediatric patients in the global ENHANCE trial: An overview Lilly Research Labratories. Medical Information on Xigris\u00ae for physicians 2005"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0004|cit4","unstructured":"Eli Lilly Xigris (drotrecogin alfa [activated]: The RESOLVE Trial Eli Lilly: Xigris: Medical information for physicians"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/00365540510031412","article-title":"Drotrecogin alpha (activated) in neonatal septic shock","volume":"37","author":"Frommhold","year":"2005","journal-title":"Scandinavian Journal of Infectious Disease"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0006|cit6","first-page":"535","article-title":"Treatment of acute infectious purpura fulminans with activated protein C","volume":"43","author":"Lokeshwar","year":"2006","journal-title":"Indian Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00043426-200401000-00008","article-title":"Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency","volume":"26","author":"Manco-Johnson","year":"2004","journal-title":"Journal of Pediatric and Hematological Oncology"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1695-4033(04)78806-2","article-title":"Recombinant human activated protein C in the treatment of children with meningococcal purpura fulminans","volume":"61","author":"Martinon-Torres","year":"2004","journal-title":"Anales de Pediatria (Barcelona, Spain)"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0010|cit10","first-page":"CS90","article-title":"Recombinant human activated protein C for severe sepsis in a neonate","volume":"8","author":"Rawicz","year":"2002","journal-title":"Medical Science Monitor"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/0885066603258652","article-title":"Drotrecogin alfa (activated) in an infant with gram-negative septic shock","volume":"19","author":"Sajan","year":"2004","journal-title":"Journal of Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/00130478-200409000-00064","article-title":"Use of activated protein C in a preterm neonate with Group B Streptococcal sepsis","volume":"5","author":"Strohler","year":"2004","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0013|cit13","first-page":"429","article-title":"Use of activated protein C in a case of paediatric septic shock","volume":"57","author":"Verre","year":"2005","journal-title":"Minerva Pediatrica"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jen.2004.07.019","article-title":"Assessment of severe sepsis in children: Experiences from pediatric patients receiving Drotrecogin Alfa (activated)","volume":"30","author":"Wyss","year":"2004","journal-title":"Journal of Emergency Nursing"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.beha.2004.03.006","article-title":"Natural anticoagulant inhibitors: activated protein C","volume":"17","author":"Aird","year":"2004","journal-title":"Best Practice and Research in Clinical Haematology"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003246-200301000-00001","article-title":"Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis","volume":"31","author":"Angus","year":"2003","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.disamonth.2003.12.003","article-title":"Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations","volume":"50","author":"Balk","year":"2004","journal-title":"Disease-A-Month"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-197801000-00001","article-title":"Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging","volume":"187","author":"Bell","year":"1978","journal-title":"Annals of Surgery"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1378\/chest.125.6.2206","article-title":"Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis","volume":"125","author":"Bernard","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/00003246-200206000-00040","article-title":"Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock","volume":"30","author":"Carcillo","year":"2002","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0749-0704(03)00013-7","article-title":"Pediatric septic shock and multiple organ failure","volume":"19","author":"Carcillo","year":"2003","journal-title":"Critical Care Clinics"},{"issue":"3","key":"10.1002\/14651858.CD005385.pub3-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003066","article-title":"G-CSF and GM-CSF for treating or preventing neonatal infections","author":"Carr","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0026|cit26","unstructured":"Catalan Agency for Health Technology Assessment and Research (CAHTA) Assessment of the scientific evidence on the use of recombinant activated C protein - (activated) alpha-drotrecogin - in severe sepsis Catalan agency for health technology assessment and research 2004"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0027|cit27","first-page":"929","article-title":"Positive end-expiratory pressure, prone positioning, and activated protein C: a critical review of meta-analyses","volume":"76","author":"Cesana","year":"2010","journal-title":"Minerva Anestesiology"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.inf.0000079362.16086.0c","article-title":"Recombinant activated protein C in pediatric sepsis","volume":"22","author":"Dalton","year":"2003","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0029|cit29","first-page":"405","article-title":"Severe sepsis in a premature neonate: protein C replacement therapy","volume":"50","author":"Carolis","year":"2008","journal-title":"Turkish Journal of Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0030|cit30","first-page":"29","article-title":"Use of protein C concentrate in neonatal period","volume":"62","author":"Carolis","year":"2010","journal-title":"Minerva Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1097\/01.CCM.0000148090.94378.6A","article-title":"Substantiating the concerns about recombinant human activated protein C use in sepsis","volume":"32","author":"Deans","year":"2004","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SHK.0b013e3181e7623e","article-title":"Protein C concentrate as adjuvant treatment in neonates with sepsis-induced coagulopathy: a pilot study","volume":"34","author":"Decembrino","year":"2010","journal-title":"Shock"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/01.CCM.0000117317.18092.E4","article-title":"Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock","volume":"32","author":"Dellinger","year":"2004","journal-title":"Critical Care Medicne"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/01.CCM.0000298158.12101.41","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008","volume":"36","author":"Dellinger","year":"2008","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0035|cit35","first-page":"706","article-title":"Postnatal bacterial infections","volume-title":"Neonatal-Perinatal Medicine: Diseases of the fetus and infant","author":"Edwards","year":"2002"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/00003246-200301001-00013","article-title":"Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action and safety concerns resulted in labeling restrictions and the need for phase IV trials","volume":"31","author":"Eichacker","year":"2003","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0037|cit37","unstructured":"European Agency for the evaluation of medicinal products: committee for proprietary medicinal products European public assessment report (EPAR) - Xigris www.emea.eu.int\/pdfs\/human\/opinion\/13844705en.pdf , www.emea.eu.int\/pdfs\/human\/press\/pr\/12130705en.pdf 2002"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0038|cit38","unstructured":"European Medicines Agency (EMA) Xigris (drotrecogin alfa (activated)) to be withdrawn due to lack of efficacy www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2011\/10\/news_detail_001373.jsp&mid=WC0b01ac058004d5c1 2011"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0039|cit39","unstructured":"Food and Drug Administration: Anti-Infective Advisory Committee FDA Clinical Review: Drotrecogin Alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, BLA # 125029\/0 www.fda.gov\/cder\/biologics\/review\/droteli112101r1.pdf www.fda.gov\/medwatch\/safety\/2005\/Xigris_dearhcp_4-21-05.pdf , www.fda.gov\/medwatch\/safety\/2005\/safety05.htm, www.fda.gov\/ohrms\/dockets\/ac\/01\/minutes\/3797m1.doc 2002 1 161"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0040|cit40","unstructured":"US Food Drug Administration FDA Drug Safety Communication. Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit www.fda.gov\/DrugsSafety\/ucm277114.htm"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0041|cit41","unstructured":"US Food Drug Administration Xigris [drotrecogin alfa (activated)]: Market withdrawal - Failure to show survival benefit www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm277143.htm 2011"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00134-008-1266-6","article-title":"Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock","volume":"34","author":"Finfer","year":"2008","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jcrc.2003.08.009","article-title":"Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis","volume":"18","author":"Fowler","year":"2003","journal-title":"Journal of Critical Care"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/CCM.0b013e318192843b","article-title":"Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions","volume":"37","author":"Gentry","year":"2009","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1111\/j.1538-7836.2003.00486.x","article-title":"A definite role for treatment with activated protein C in sepsis? Standard use is premature","volume":"1","author":"Girbes","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003495-200464080-00004","article-title":"Advances in sepsis therapy","volume":"64","author":"Gluck","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.PCC.0000217470.68764.36","article-title":"ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis","volume":"7","author":"Goldstein","year":"2006","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.PCC.0000149131.72248.E6","article-title":"International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics","volume":"6","author":"Goldstein","year":"2005","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1-126, iii-xiii","DOI":"10.3310\/hta9110","article-title":"Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation","volume":"9","author":"Green","year":"2005","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD005385.pub3-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004205","article-title":"Pentoxifylline for neonatal sepsis","author":"Haque","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1345\/aph.1A283","article-title":"New and emerging therapies for sepsis","volume":"36","author":"Healy","year":"2002","journal-title":"Annals of Pharmacotherapeutics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1542\/peds.107.1.14","article-title":"Collaborative quality improvement for neonatal intensive care. NIC\/Q Project Investigators of the Vermont Oxford Network","volume":"107","author":"Horbar","year":"2001","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMra021333","article-title":"The pathophysiology and treatment of sepsis","volume":"348","author":"Hotchkiss","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00000441-200410000-00002","article-title":"Coagulation in sepsis","volume":"328","author":"Jagneaux","year":"2004","journal-title":"American Journal of Medical Science"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0055|cit55","first-page":"676","article-title":"Developmental Immunology","volume-title":"Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant","volume":"2","author":"Kapur","year":"2002"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0056|cit56","first-page":"943","article-title":"Bacterial Sepsis and Meningitis","volume-title":"Infectious Diseases of the Fetus and Newborn Infant","author":"Klein","year":"2001"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.PCC.0000074266.10576.9B","article-title":"Mortality rates in pediatric septic shock with and without multiple organ system failure","volume":"4","author":"Kutko","year":"2003","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/00003246-199904000-00042","article-title":"Effect of immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo controlled, double-blind trial","volume":"27","author":"Lauterbach","year":"1999","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1164\/rccm.200612-1803OC","article-title":"Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)","volume":"176","author":"Levi","year":"2007","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0061|cit61","first-page":"105","article-title":"Treatment with recombinant human activated protein C: one size does not fit all","volume":"15","author":"Levi","year":"2011","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference","volume":"31","author":"Levy","year":"2003","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0063|cit63","first-page":"25","article-title":"Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection","volume-title":"Infectious Diseases of the Fetus and Newborn Infant","author":"Lewis","year":"2001"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0064|cit64","unstructured":"Lilly Lilly Announces Withdrawal of Xigris\u00ae Following Recent Clinical Trial Results https:\/\/investor.lilly.com\/releasedetail2.cfm?ReleaseID=617602 2011"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.inf.0000131633.74921.90","article-title":"Trends in sepsis-related neonatal mortality in the United States, 1985-1998","volume":"23","author":"Lukacs","year":"2004","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMsa020969","article-title":"An economic evaluation of activated protein C treatment for severe sepsis","volume":"347","author":"Manns","year":"2002","journal-title":"New England Journal Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.ccx.0000134877.60312.f3","article-title":"Sepsis: current status, future prospects","volume":"10","author":"Marshall","year":"2004","journal-title":"Current opinion in Critical Care"},{"issue":"4","key":"10.1002\/14651858.CD005385.pub3-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004388.pub4","article-title":"Human recombinant activated protein C for severe sepsis","author":"Marti-Carvajal","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajog.2005.04.046","article-title":"Recombinant human activated protein C treatment of septic shock syndrome in a patient at 18th week of gestation: a case report","volume":"193","author":"Medve","year":"2005","journal-title":"American Journal of Obstetrics and Gynecology"},{"issue":"885","key":"10.1002\/14651858.CD005385.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0140-6736(93)92296-6","article-title":"The CRIB (clinical risk index for babies) score: a tool for assessing initial neonatal risk and comparing performance of neonatal intensive care units. The International Neonatal Network","volume":"342","author":"The International Neonatal Network","year":"1993","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0071|cit71","unstructured":"National Institute for clinical excellence Drotrecogin alfa (activated) for severe sepsis Technology Appraisal Guidance (www.nice.org.uk\/TA084guidance) 2004 1 31"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0272-5231(03)00102-3","article-title":"New approaches to the treatment of sepsis","volume":"24","author":"O'Brien","year":"2003","journal-title":"Clinics in Chest Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005385.pub3-BIB0073|cit73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005248.pub2","article-title":"Intravenous immunoglobulin for preventing infection in preterm and\/or low-birth-weight infants","author":"Ohlsson","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD005385.pub3-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001239.pub3","article-title":"Intravenous immunoglobulin for suspected or subsequently proven infection in neonates","author":"Ohlsson","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(07)60383-3","article-title":"Can we RESOLVE the treatment of sepsis?","volume":"369","author":"Opal","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","article-title":"Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm","volume":"92","author":"Papile","year":"1978","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1097\/01.CCM.0000145904.97821.0D","article-title":"Pediatric considerations","volume":"32","author":"Parker","year":"2004","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.PCC.0000149307.02324.05","article-title":"Pediatric definitions for sepsis: it's about time!","volume":"6","author":"Parker","year":"2005","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0079|cit79","first-page":"357","article-title":"Use of protein C concentrate in critical conditions: clinical experience in pediatric patients with sepsis","volume":"70","author":"Pettenazzo","year":"2004","journal-title":"Minerva Anestesiologica"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00003246-199605000-00004","article-title":"PRISM III: an updated Pediatric Risk of Mortality score","volume":"24","author":"Pollack","year":"1996","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1007\/s00134-010-1977-3","article-title":"Statistical analysis plan for PROWESS SHOCK study","volume":"36","author":"Thompson","year":"2010","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1007\/s00134-011-2272-7","article-title":"Unblinding plan of PROWESS-SHOCK trial","volume":"37","author":"Ranieri","year":"2011","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00000441-200410000-00003","article-title":"Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock","volume":"328","author":"Rice","year":"2004","journal-title":"American Journal of Medical Science"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.med.56.082103.104356","article-title":"Therapeutic intervention and targets for sepsis","volume":"56","author":"Rice","year":"2005","journal-title":"Annual Review of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1067\/mpd.2001.109608","article-title":"SNAP-II and SNAPPE-II: Simplified newborn illness severity and mortality risk scores","volume":"138","author":"Richardson","year":"2001","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s001340050317","article-title":"Pediatric index of mortality (PIM): a mortality prediction model for children in intensive care unit","volume":"23","author":"Shann","year":"1997","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1186\/cc9382","article-title":"Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated)","volume":"14","author":"Shorr","year":"2010","journal-title":"Critical Care"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1542\/peds.102.2.e18","article-title":"Decline in sepsis-associated neonatal and infant deaths in the United States, 1979 through 1994","volume":"102","author":"Stoll","year":"1998","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1056\/NEJMoa012657","article-title":"Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants","volume":"347","author":"Stoll","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0146-0005(03)00046-6","article-title":"Infections in VLBW infants: studies from the NICHD Neonatal Research Network","volume":"27","author":"Stoll","year":"2003","journal-title":"Seminars in Perinatology"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.292.19.2357","article-title":"Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection","volume":"292","author":"Stoll","year":"2004","journal-title":"Journal of American Medical Association"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/CCM.0b013e3181935102","article-title":"Recombinant human activated protein C, package labeling, and hemorrhage risk","volume":"37","author":"Sweeney","year":"2009","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1056\/NEJMct0808063","article-title":"Activated protein C for severe sepsis","volume":"361","author":"Toussaint","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"103S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.103S","article-title":"Global ENHANCE results indicate organ function improvement with drotrecogin alfa (activated) in severe sepsis patients","volume":"124","author":"Vincent","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1097\/01.CCM.0000181729.46010.83","article-title":"Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment","volume":"33","author":"Vincent","year":"2005","journal-title":"Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMsb020574","article-title":"Risks and benefits of activated protein C treatment for severe sepsis","volume":"347","author":"Warren","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1164\/rccm.200207-682OC","article-title":"The epidemiology of severe sepsis in children in the United States","volume":"167","author":"Watson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bpa.2003.12.005","article-title":"The systemic inflammatory response syndrome","volume":"18","author":"Weigand","year":"2004","journal-title":"Best Practice and Research Clinical Anaesthesiology"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1378\/chest.120.3.915","article-title":"Low levels of protein C are associated with poor outcome in severe sepsis","volume":"120","author":"Yan","year":"2001","journal-title":"Chest"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PCC.0b013e3181d903f6","article-title":"Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study","volume":"12","author":"Zimmerman","year":"2011","journal-title":"Pediatric Critical Care Medicine"},{"key":"10.1002\/14651858.CD005385.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00001503-200406000-00005","article-title":"Recent developments in the pharmacological approach to pediatric critical care","volume":"17","author":"Zuppa","year":"2004","journal-title":"Current Opinion in Anaesthesiology"},{"issue":"2","key":"10.1002\/14651858.CD005385.pub3-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005385.pub2","article-title":"Recombinant human activated protein C for severe sepsis in neonates","author":"Kylat","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005385.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:48:46Z","timestamp":1628531326000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD005385.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neonatal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,18]]},"references-count":103,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005385.pub3","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718490385.793497349","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,18]]}}}